Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
Lijo Chacko is the Chief Executive Officer – Middle East & Africa at Sigachi Industries
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
mRNA-1010 demonstrated superior relative vaccine efficacy
Subscribe To Our Newsletter & Stay Updated